JP2002262827A - Serum lipid improving composition containing mannooligosaccharide - Google Patents
Serum lipid improving composition containing mannooligosaccharideInfo
- Publication number
- JP2002262827A JP2002262827A JP2001070385A JP2001070385A JP2002262827A JP 2002262827 A JP2002262827 A JP 2002262827A JP 2001070385 A JP2001070385 A JP 2001070385A JP 2001070385 A JP2001070385 A JP 2001070385A JP 2002262827 A JP2002262827 A JP 2002262827A
- Authority
- JP
- Japan
- Prior art keywords
- mannose
- composition
- coffee
- oligosaccharide
- oligosaccharides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 46
- 150000002632 lipids Chemical class 0.000 title claims abstract description 20
- 210000002966 serum Anatomy 0.000 title claims abstract description 18
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 36
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims abstract description 34
- 235000013353 coffee beverage Nutrition 0.000 claims abstract description 31
- 235000016213 coffee Nutrition 0.000 claims abstract description 30
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 28
- 150000002772 monosaccharides Chemical class 0.000 claims abstract description 21
- 229920000057 Mannan Polymers 0.000 claims abstract description 11
- 241000533293 Sesbania emerus Species 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 25
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 16
- 235000013305 food Nutrition 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 13
- 229930182830 galactose Natural products 0.000 claims description 7
- 230000007062 hydrolysis Effects 0.000 claims description 7
- 238000006460 hydrolysis reaction Methods 0.000 claims description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 238000000605 extraction Methods 0.000 abstract description 15
- 230000003301 hydrolyzing effect Effects 0.000 abstract description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 20
- 235000000346 sugar Nutrition 0.000 description 15
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 239000003456 ion exchange resin Substances 0.000 description 6
- 229920003303 ion-exchange polymer Polymers 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 235000012054 meals Nutrition 0.000 description 6
- 239000011347 resin Substances 0.000 description 6
- 229920005989 resin Polymers 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 239000003014 ion exchange membrane Substances 0.000 description 5
- 230000035790 physiological processes and functions Effects 0.000 description 5
- 238000006116 polymerization reaction Methods 0.000 description 5
- 238000001179 sorption measurement Methods 0.000 description 5
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 description 4
- 244000247812 Amorphophallus rivieri Species 0.000 description 4
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 4
- 244000060011 Cocos nucifera Species 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 229920000926 Galactomannan Polymers 0.000 description 4
- 229920002581 Glucomannan Polymers 0.000 description 4
- 229920002752 Konjac Polymers 0.000 description 4
- 238000005903 acid hydrolysis reaction Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 229940046240 glucomannan Drugs 0.000 description 4
- 239000000252 konjac Substances 0.000 description 4
- 235000010485 konjac Nutrition 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- -1 β-mannose biose Chemical class 0.000 description 4
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 3
- GUBGYTABKSRVRQ-PZPXDAEZSA-N 4β-mannobiose Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-PZPXDAEZSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 235000013162 Cocos nucifera Nutrition 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000007071 enzymatic hydrolysis Effects 0.000 description 3
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 3
- 235000021539 instant coffee Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 241000234435 Lilium Species 0.000 description 2
- 229920000161 Locust bean gum Polymers 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- DKXNBNKWCZZMJT-UHFFFAOYSA-N O4-alpha-D-Mannopyranosyl-D-mannose Natural products O=CC(O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O DKXNBNKWCZZMJT-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 239000003377 acid catalyst Substances 0.000 description 2
- GZCGUPFRVQAUEE-KVTDHHQDSA-N aldehydo-D-mannose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O GZCGUPFRVQAUEE-KVTDHHQDSA-N 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000004042 decolorization Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000006694 eating habits Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000711 locust bean gum Substances 0.000 description 2
- 235000010420 locust bean gum Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- GZCGUPFRVQAUEE-UHFFFAOYSA-N 2,3,4,5,6-pentahydroxyhexanal Chemical compound OCC(O)C(O)C(O)C(O)C=O GZCGUPFRVQAUEE-UHFFFAOYSA-N 0.000 description 1
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 description 1
- 241000234270 Amaryllidaceae Species 0.000 description 1
- 229920000189 Arabinogalactan Polymers 0.000 description 1
- 239000001904 Arabinogalactan Substances 0.000 description 1
- 102100022210 COX assembly mitochondrial protein 2 homolog Human genes 0.000 description 1
- 108010059892 Cellulase Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 101000900446 Homo sapiens COX assembly mitochondrial protein 2 homolog Proteins 0.000 description 1
- 101000879758 Homo sapiens Sjoegren syndrome nuclear autoantigen 1 Proteins 0.000 description 1
- 101000649946 Homo sapiens Vacuolar protein sorting-associated protein 29 Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241000234479 Narcissus Species 0.000 description 1
- 102100037330 Sjoegren syndrome nuclear autoantigen 1 Human genes 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- FTNIPWXXIGNQQF-UHFFFAOYSA-N UNPD130147 Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(OC3C(OC(OC4C(OC(O)C(O)C4O)CO)C(O)C3O)CO)C(O)C2O)CO)C(O)C1O FTNIPWXXIGNQQF-UHFFFAOYSA-N 0.000 description 1
- LUEWUZLMQUOBSB-UHFFFAOYSA-N UNPD55895 Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(OC3C(OC(O)C(O)C3O)CO)C(O)C2O)CO)C(O)C1O LUEWUZLMQUOBSB-UHFFFAOYSA-N 0.000 description 1
- 102100028290 Vacuolar protein sorting-associated protein 29 Human genes 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- YETHWGOYCQLNKG-FHERGOJNSA-N alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->6)]-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->2)-D-Manp Chemical compound O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@H]1O[C@@H]1[C@@H](O[C@@H]2[C@H]([C@@H](O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YETHWGOYCQLNKG-FHERGOJNSA-N 0.000 description 1
- LHAOFBCHXGZGOR-NAVBLJQLSA-N alpha-D-Manp-(1->3)-alpha-D-Manp-(1->2)-alpha-D-Manp Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1 LHAOFBCHXGZGOR-NAVBLJQLSA-N 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000019312 arabinogalactan Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- LUEWUZLMQUOBSB-MHJOMNRISA-N beta-D-Manp-(1->4)-beta-D-Manp-(1->4)-beta-D-Manp-(1->4)-D-Manp Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3[C@H](OC(O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@@H](O)[C@H]1O LUEWUZLMQUOBSB-MHJOMNRISA-N 0.000 description 1
- OCIBBXPLUVYKCH-KKQGKRJZSA-N beta-D-Manp-(1->4)-beta-D-Manp-(1->4)-beta-D-Manp-(1->4)-beta-D-Manp-(1->4)-beta-D-Manp-(1->4)-D-Manp Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3[C@H](O[C@@H](O[C@@H]4[C@H](O[C@@H](O[C@@H]5[C@H](OC(O)[C@@H](O)[C@H]5O)CO)[C@@H](O)[C@H]4O)CO)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@@H](O)[C@H]1O OCIBBXPLUVYKCH-KKQGKRJZSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 229940106157 cellulase Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000002361 compost Substances 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000020805 dietary restrictions Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000000909 electrodialysis Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940059442 hemicellulase Drugs 0.000 description 1
- 108010002430 hemicellulase Proteins 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000002440 industrial waste Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- FYGDTMLNYKFZSV-UHFFFAOYSA-N mannotriose Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(O)C(O)C2O)CO)C(O)C1O FYGDTMLNYKFZSV-UHFFFAOYSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000008635 plant growth Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000006276 transfer reaction Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
- Y02P60/80—Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
- Y02P60/87—Re-use of by-products of food processing for fodder production
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Fodder In General (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Tea And Coffee (AREA)
- Jellies, Jams, And Syrups (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は、マンノースを主体とし
たオリゴ糖類を主成分とする血清脂質の改善作用を有す
る組成物、およびその組成物を用いた飲食物および飼料
に関するものである。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a composition mainly composed of oligosaccharides mainly composed of mannose and having an effect of improving serum lipids, and to a food, a food and a feed using the composition.
【0002】食生活と生活習慣病との関わりが重大な関
心事となっている近年、食品本来の持つ生理機能が注目
を浴びている。特に、高血圧、糖尿、高脂血や脂肪肝等
の生活習慣病の発現率が高まってきている中、これらの
原因と考えられている肥満を日常の食生活で如何に防止
するかが大きな課題となっている。肥満には脂質が大き
く関与しているが、血清中の脂質の上昇を抑制する食素
材が求められている。従来、食物繊維が脂質制御の目的
で利用されてきたが、風味が変わったり食感が変化した
り、また、経済的にも欠点が残った。[0002] In recent years, where the relationship between diet and lifestyle-related diseases has become a major concern, the physiological functions of foods have attracted attention. In particular, as the incidence of lifestyle-related diseases such as hypertension, diabetes, hyperlipidemia, and fatty liver is increasing, how to prevent obesity, which is thought to be the cause of these diseases, in daily eating habits is a major issue. It has become. Lipids are greatly involved in obesity, and there is a need for a food material that suppresses an increase in serum lipids. Conventionally, dietary fiber has been used for the purpose of controlling lipids, but its flavor and texture have changed, and its disadvantages remain economically.
【0003】近年、D−マンノースがβ−1,4結合し
た化合物であるβ−1,4マンノビオースなどのβ−
1,4−マンノオリゴ糖の持つ生理機能が注目されてお
り、家畜の有害菌汚染防止物質としても知られている
(特開平8−38064)。また人間の糖タンパク質の
糖鎖の重要な部分構造にはD−マンノースがβ−1,4
結合したマンノオリゴ糖が含まれており、飲食品原料と
してのみならず、医薬品の原料としての応用も期待され
ている(特昭58−21278、特開平8−998
9)。In recent years, β-mannose biose such as β-1,4 mannobiose, which is a compound in which D-mannose is β-1,4 bonded, has been developed.
The physiological functions of 1,4-mannooligosaccharides have attracted attention, and are also known as substances for preventing harmful bacterial contamination of livestock (Japanese Patent Application Laid-Open No. 8-38064). D-mannose is β-1,4 as an important partial structure of the sugar chain of human glycoprotein.
It contains bound manno-oligosaccharides and is expected to be used not only as a raw material for food and drink but also as a raw material for pharmaceuticals (Japanese Patent Publication No. 58-21278, Japanese Patent Application Laid-Open No. 8-998).
9).
【0004】また、本発明は未利用資源の有効活用にも
関するものである。コーヒーの抽出残渣は従来、そのほ
とんどが焼却あるいは産業廃棄物として処理されてき
た。近年になり、コーヒー抽出残渣が堆肥原料あるいは
活性炭原料として利用されるようになってきたが、それ
らは未利用資源の高度利用という観点からは十分とはい
えず、更なるコーヒー抽出残渣の高度利用の方法を確立
することは重要課題となっている。[0004] The present invention also relates to the effective use of unused resources. Conventionally, most coffee extraction residues have been incinerated or treated as industrial waste. In recent years, coffee extraction residues have been used as a raw material for compost or activated carbon.However, they are not sufficient from the viewpoint of advanced utilization of unused resources. It is an important issue to establish the method of the above.
【0005】[0005]
【従来の技術および発明が解決しようとする課題】従
来、マンノース残基を有する単糖、およびオリゴ糖類の
生理機能については有害細菌の感染を予防するために飼
料へ添加する方法(特開平08−38064)、植物の
生長を促進させるために植物または土壌に施用する方法
(特開昭63−215606)等が提案されているが、
ヒトが摂取するにあたり、どのような生理機能を示すか
は、ほとんど不明であり、コンニャクの加水分解物であ
るグルコマンナンオリゴ糖を摂取することによるビフイ
ドバクテリウム増殖方法(特開昭58−212780)
が提案されているのみである。しかもその内容は、ビフ
イドバクテリウム菌を増殖させる方法であり、その他の
腸内有害菌も増殖させてしまう虞れがある。また、コン
ニャクの加水分解物には糖鎖中にマンノース残基以外に
グルコース残基が多く含まれており、マンノース残基以
外の糖残基がほとんど含まれていないマンノオリゴ糖に
ついての報告はまだない。2. Description of the Related Art Conventionally, the physiological functions of monosaccharides and oligosaccharides having a mannose residue are added to feed in order to prevent infection by harmful bacteria (Japanese Patent Application Laid-Open No. 08-2008). 38064), a method of applying to plants or soil to promote plant growth (JP-A-63-215606) and the like have been proposed.
It is almost unknown what physiological function is exhibited by humans, and a method for growing bifidobacteria by ingesting glucomannan oligosaccharide, which is a hydrolyzate of konjac (Japanese Patent Application Laid-Open No. 58-21780) )
Is only proposed. Moreover, the method is a method of growing bifidobacteria, and there is a possibility that other intestinal harmful bacteria may also grow. In addition, the konjac hydrolyzate contains a large amount of glucose residues other than mannose residues in the sugar chain, and there is no report on a manno-oligosaccharide containing almost no sugar residues other than mannose residues. .
【0006】マンノース残基を有する単糖類およびオリ
ゴ糖類の製造方法としては、例えば、コンニャク、ユリ
等に含まれるグルコマンナンや、グアガム、ローカスト
ビーンガム等に含まれるガラクトマンナン等を酸や酵素
で加水分解する方法(特開昭63−49093)、コプ
ラミールから酵素加水分解によりマンノビオースを製造
する方法(特開平11−18793)等が提案されてい
る。As a method for producing monosaccharides and oligosaccharides having a mannose residue, for example, glucomannan contained in konjac, lily and the like, and galactomannan contained in guar gum, locust bean gum and the like are hydrolyzed with an acid or an enzyme. A method of decomposing (JP-A-63-49093) and a method of producing mannobiose from copra meal by enzymatic hydrolysis (JP-A-11-18793) have been proposed.
【0007】しかし、グルコマンナンやガラクトマンナ
ンの加水分解物からグルコース、ガラクトース等が混在
しマンノースを主要構成糖とするマンノオリゴ糖と呼ぶ
にはかけ離れた物であった。However, glucomannan or galactomannan hydrolyzate is mixed with glucose, galactose, etc., and is far from a manno-oligosaccharide having mannose as a main constituent sugar.
【0008】また、コーヒー抽出残渣を加水分解するこ
とにより、糖鎖中にマンノース残基以外の糖残基の含有
量が少ないマンノオリゴ糖類を得ることはできる(米国
特許第4,484,012号、米国特許第4,508,
745号、米国特許第4,798,730)が、着色物
質、脂質、蛋白質、塩、酸等が混在しているため、食
品、医薬品等への適用が制限される。[0008] Manno-oligosaccharides having a low content of sugar residues other than mannose residues in the sugar chain can be obtained by hydrolyzing the coffee extraction residue (US Pat. No. 4,484,012, U.S. Pat. No. 4,508,
No. 745, U.S. Pat. No. 4,798,730) contains a coloring substance, a lipid, a protein, a salt, an acid and the like.
【0009】さらに、コプラミールを加水分解およびマ
ンノースを縮合または転移反応させることにより、糖鎖
中にマンノース残基以外の糖残基の含有量が少ないマン
ノオリゴ糖類を得ることができる(特開平11−018
791)が、これらの生理機能および飲食料品への利用
については未知である。通常の食生活習慣の大幅な変更
を伴うことなく、しかも血清脂質の改善作用が優れ経済
的で簡便な飲食品を提供することを目的としている。Furthermore, by hydrolyzing copra meal and subjecting mannose to condensation or transfer reaction, mannooligosaccharides having a low content of sugar residues other than mannose residues in the sugar chain can be obtained (JP-A-11-018).
791), however, their physiological functions and their use in food and drink are unknown. It is an object of the present invention to provide an economical and simple food and drink which is excellent in the action of improving serum lipids without a significant change in normal eating habits.
【0010】[0010]
【課題を解決するための手段】本発明者らは、これらの
ような課題を解決するために鋭意検討の結果、マンナン
を多く含む食品素材、主に、コーヒー抽出粕加水分解物
から、糖鎖中にマンノース残基以外の糖残基の含有量が
少ない重合度1〜10のマンノオリゴ糖類又はマンノー
スとグルコースおよびガラクトースのような単糖類の少
なくとも1種とが1〜10分子結合したマンノースを主
体としたオリゴ糖類に血清脂質の改善作用を有すること
を見いだし、本発明を完成するに至った。さらに、無着
色、無酸の糖鎖中にマンノース残基以外の糖残基の含有
量が少ない重合度1〜10のマンノオリゴ糖類を得るこ
とで、食品への適用範囲を飛躍的に広げることができる
ことを見いだした。Means for Solving the Problems The inventors of the present invention have conducted intensive studies to solve these problems, and as a result, have found that a food material containing a large amount of mannan, mainly a coffee extract lees hydrolyzate, Mannose oligosaccharides having a low content of sugar residues other than mannose residues in the degree of polymerization of 1 to 10 or mannose and at least one kind of monosaccharides such as glucose and galactose are mainly composed of mannose in which 1 to 10 molecules are bonded. The inventors have found that the oligosaccharides have an effect of improving serum lipids, and have completed the present invention. Further, by obtaining mannooligosaccharides having a degree of polymerization of 1 to 10 having a low content of sugar residues other than mannose residues in an uncolored, acid-free sugar chain, the range of application to food can be dramatically expanded. I found what I could do.
【0011】本発明は、マンノースを主体とした単糖類
が1〜10分子結合したオリゴ糖類又はマンノースとグ
ルコースおよびガラクトースのような単糖類の少なくと
も1種とが1〜10分子結合したマンノースを主体とし
たオリゴ糖類を主成分とすることを特徴とする血清脂質
の改善作用を有する組成物に関する。当該組成物は、マ
ンノースもしくはマンノースを主体とした単糖が2〜1
0分子結合した単一の化合物、または、それらの中から
選ばれた2種以上のオリゴ糖を主成分とする組成物を意
味する。本発明の組成物において、マンノースが1〜1
0分子結合した単一の化合物ないしはそれらの中から選
ばれた2種以上の化合物を含有する血清脂質の改善作用
を有する組成物であることが望ましい。The present invention relates to an oligosaccharide comprising 1 to 10 molecules of a monosaccharide mainly composed of mannose, or a mannose mainly composed of 1 to 10 molecules of mannose and at least one monosaccharide such as glucose and galactose. The present invention relates to a composition having an activity of improving serum lipids, characterized in that the composition has an oligosaccharide as a main component. The composition comprises mannose or a mannose-based monosaccharide of 2 to 1%.
It refers to a single compound with 0 molecules bonded, or a composition mainly composed of two or more oligosaccharides selected from them. In the composition of the present invention, mannose is 1 to 1;
It is desirable that the composition be a single compound having 0 molecules bonded or a composition containing two or more compounds selected from them, which has an effect of improving serum lipids.
【0012】本発明の組成物において、総固形分に対
し、マンノースを主体とする単糖類が1〜10分子結合
したオリゴ糖類の合計含有割合が60重量%以上が好ま
しく、80重量%以上がさらに好ましい。In the composition of the present invention, the total content of oligosaccharides having 1 to 10 monosaccharides mainly composed of mannose bonded to the total solid content is preferably at least 60% by weight, more preferably at least 80% by weight. preferable.
【0013】本発明における組成物の糖組成においては
マンノース残基の割合が70重量%以上、更に好ましく
は80重量%以上であるものが望ましい。マンノース残
基の割合が70%に満たないと、効果が大きく期待でき
ないとともに、甘味度も増し適用の幅が狭まる傾向にあ
る。構成糖としては、マンノース以外には、加水分解す
る出発物質にもよるがグルコース、ガラクトースなどが
含まれるが必要に応じて除去することもできる。組成物
中の遊離のマンノース含量については50%以下に抑え
られたものが望ましい。50重量%を越えると、マンノ
ース由来の苦味のために、適用の範囲に制約を受ける傾
向にある。さらに、マンノースを主体としたオリゴ糖類
は、マンノースが2〜6分子結合したオリゴ糖類である
ことが好ましい。そして、その結合様式は、βー1,4
結合であることが好ましい。In the saccharide composition of the composition of the present invention, the ratio of mannose residues is preferably 70% by weight or more, more preferably 80% by weight or more. If the ratio of mannose residues is less than 70%, the effect cannot be expected to be large, and the sweetness is also increased, and the range of application tends to be narrowed. The constituent sugars include glucose, galactose, etc., depending on the starting material to be hydrolyzed, in addition to mannose, but can be removed as necessary. The content of free mannose in the composition is desirably suppressed to 50% or less. If it exceeds 50% by weight, the range of application tends to be restricted due to bitterness derived from mannose. Further, the oligosaccharide mainly composed of mannose is preferably an oligosaccharide having 2 to 6 molecules of mannose bonded thereto. And the binding mode is β-1,4
It is preferably a bond.
【0014】本発明においては、マンナンを加水分解処
理することによって得られたマンノースを主成分とする
血清脂質の改善作用を有する組成物が好ましい。また、
当該マンナンがコーヒー豆および/またはコーヒー抽出
残渣から得られるものであることが好ましい。In the present invention, a composition having an activity of improving serum lipids containing mannose as a main component obtained by hydrolyzing mannan is preferred. Also,
It is preferred that the mannan is obtained from coffee beans and / or coffee extraction residue.
【0015】さらに、本発明においては、コーヒー抽出
残渣を加水分解処理することによって得られたマンノー
スを主成分とする血清脂質の改善作用を有する組成物が
好ましい。Further, in the present invention, a composition having an effect of improving serum lipids containing mannose as a main component obtained by hydrolyzing a coffee extraction residue is preferred.
【0016】また、本発明は、上記に説明した本発明に
係る組成物を含有する飲食物および飼料にも関する。本
発明に係る組成物は、粉末、顆粒、錠剤、シロップ状な
どあらゆる形態とすることができ、他の飲食品や飼料な
どに幅広い分野への応用が可能である。そして、口から
摂取することにより血清脂質の改善作用を発揮する。そ
の添加率は、特に制限はないが、望まれる飲食品ないし
は飼料の特性によって適宜選択される。The present invention also relates to foods and drinks and feeds containing the above-described composition according to the present invention. The composition according to the present invention can be in any form, such as powder, granules, tablets, and syrup, and can be applied to a wide range of fields such as other foods and drinks and feeds. And, by taking it through the mouth, it exerts an effect of improving serum lipids. The rate of addition is not particularly limited, but is appropriately selected depending on the desired characteristics of the food or drink or feed.
【0017】本発明の組成物は、例えばココナッツ椰子
から得られるコプラミール、フーク、南アフリカ産椰子
科植物HuacraPalm、ツクネイモマンナン、ヤ
マイモマンナンよりマンナンを抽出後、酸加水分解、高
温加熱加水分解、酵素加水分解の中から選ばれる1種ま
たは2種以上の方法で処理し、活性炭処理、吸着樹脂処
理、イオン交換樹脂処理、イオン交換膜処理等の方法で
精製された糖混合物および/またはコンニャクイモ、ユ
リ、スイセン、ヒガンバナ等に含まれるグルコマンナ
ン、ローカストビーンガム、グアーガム等に含まれるガ
ラクトマンナンを酸加水分解、高温加熱加水分解、酵素
加水分解の中から選ばれる1種または2種以上の方法で
処理し、活性炭処理、吸着樹脂処理、イオン交換樹脂処
理、イオン交換膜処理等の方法で分離精製し構成糖とし
てマンノースの比率を高めたものであってもよい。The composition of the present invention is obtained by extracting mannan from, for example, copra meal, hook obtained from coconut coconut palm, HuacraPalm from South Africa, tsukuneimomannan, and yamimomannan, and then subjecting to acid hydrolysis, high temperature heat hydrolysis, enzyme hydrolysis. A sugar mixture and / or konjac potato, lily, which are treated by one or more methods selected from the group consisting of: activated carbon treatment, adsorption resin treatment, ion exchange resin treatment, ion exchange membrane treatment, etc. Glucomannan contained in narcissus, amaryllidaceae, etc., galactomannan contained in locust bean gum, guar gum, etc. is treated by one or more methods selected from acid hydrolysis, high temperature heat hydrolysis, and enzyme hydrolysis. , Activated carbon treatment, adsorption resin treatment, ion exchange resin treatment, ion exchange membrane treatment Or it may be an increased ratio of mannose as a way to separation and purification constituent sugars and the like.
【0018】さらに、コーヒー生豆または焙煎したコー
ヒー豆を酸加水分解、高温加熱加水分解、酵素加水分解
の中から選ばれる1種または2種以上の方法で処理し、
活性炭処理、吸着樹脂処理、イオン交換樹脂処理、イオ
ン交換膜処理等の方法で精製することによって得ること
ができる。Further, the green coffee beans or the roasted coffee beans are treated by one or more methods selected from the group consisting of acid hydrolysis, high temperature heat hydrolysis and enzymatic hydrolysis,
It can be obtained by purification by a method such as activated carbon treatment, adsorption resin treatment, ion exchange resin treatment, or ion exchange membrane treatment.
【0019】あるいは、使用済みコーヒー残渣を、酸加
水分解、高温加熱加水分解、酵素加水分解の中から選ば
れる1種または2種以上の方法で可溶化処理した水溶液
を活性炭処理、吸着樹脂処理、イオン交換樹脂処理、イ
オン交換膜処理等の方法で精製することによって得るこ
とができる。Alternatively, an aqueous solution obtained by solubilizing a used coffee residue by one or more methods selected from acid hydrolysis, high-temperature heat hydrolysis and enzymatic hydrolysis is treated with activated carbon, adsorbed resin, It can be obtained by purification by a method such as ion exchange resin treatment and ion exchange membrane treatment.
【0020】一般に、焙煎粉砕コーヒーを商業用の抽出
器にて抽出すると、その際に焙煎コーヒーに含まれるガ
ラクトマンナンの側鎖であるガラクトースが可溶化した
り、アラビノガラクタンが加水分解によって可溶化す
る。従って、コーヒー残渣中にはマンナンが豊富であ
り、しかも直鎖構造をとっているものと推定される。一
方、セルロースは分解されにくく残渣として残っている
が、セルロースを分解せずにマンナンを特異的に加水分
解する条件を適宜選択することにより、マンノースを主
体とするオリゴ糖を得ることができる。Generally, when roasted and ground coffee is extracted with a commercial extractor, galactose which is a side chain of galactomannan contained in the roasted coffee is solubilized, and arabinogalactan is hydrolyzed. Solubilize. Therefore, it is presumed that coffee residue is rich in mannan and has a linear structure. On the other hand, although cellulose is hardly decomposed and remains as a residue, an oligosaccharide mainly composed of mannose can be obtained by appropriately selecting conditions for specifically hydrolyzing mannan without decomposing cellulose.
【0021】本発明において使用されるコーヒー抽出残
渣は通常の液体コーヒーあるいはインスタントコーヒー
製造工程において抽出されたものであれば、常圧下、加
圧下抽出であろうと、またいかなる起源、製法のコーヒ
ー抽出残渣であっても使用することができる。[0021] The coffee extraction residue used in the present invention may be extracted under normal pressure or pressure, as long as it is extracted in a usual liquid coffee or instant coffee production process, and coffee extraction residue of any origin and production method. Can also be used.
【0022】コーヒー抽出残渣を酸および/または熱に
より加水分解しオリゴ糖類を高純度に含むように調製し
た組成物を液体コーヒー、インスタントコーヒー等にそ
のまま添加して使用することもできるが、必要に応じて
活性炭、イオン交換樹脂等で脱色、脱臭、脱酸等の精製
処理をしたものを添加した方がコーヒー本来の味、香り
のより豊かなコーヒーを提供することができる。A composition prepared by hydrolyzing a coffee extraction residue with acid and / or heat and containing oligosaccharides with high purity can be used as it is by adding it directly to liquid coffee, instant coffee or the like. Accordingly, it is possible to provide a coffee having a richer original taste and aroma by adding a product which has been subjected to a purification treatment such as decolorization, deodorization, and deoxidation with activated carbon, an ion exchange resin or the like.
【0023】更に、カラムクロマトグラフィー等で特定
の重合度をもつマンノオリゴ糖に分画した上で使うこと
もできる。以下に本発明において、コーヒー抽出残渣か
らマンノースを主成分とする単糖類が1〜10分子結合
したオリゴ糖類を含有する組成物を製造する代表的な方
法を述べるが、必ずしも以下の製法に限定されるもので
はない。Further, it can be used after fractionating into mannooligosaccharides having a specific polymerization degree by column chromatography or the like. Hereinafter, in the present invention, a typical method for producing a composition containing oligosaccharides in which monosaccharides containing mannose as a main component are bonded in 1 to 10 molecules from a coffee extraction residue is described, but is not necessarily limited to the following production method. Not something.
【0024】コーヒー抽出残渣を分解する方法として
は、酸および/または高温により加水分解する方法と酵
素により分解する方法が挙げられる。酸および/または
高温により加水分解する方法としては特開昭61−96
947号、特開平2−200147号等に開示されてい
る。商業用のコーヒー多段式抽出系において出てくる使
用済みコーヒー残渣を反応容器中において酸触媒を添加
して加水分解することもできるし、酸触媒を添加せずに
高温で短時間処理して加水分解することによっても得る
ことができる。管形栓流反応器を使用するのが便利であ
るが比較的高温で短時間の反応を行わせるのに向いてい
るものならば、いかなる反応器を使用しても良好な結果
が得られる。反応時間と反応温度を調節し、可溶化して
加水分解させることによってDP10〜40のマンナン
をDP1〜10のマンノオリゴ糖に分解し、その後コー
ヒー残渣と分離してマンノオリゴ糖類を得る。Methods for decomposing the coffee extraction residue include a method of hydrolyzing with an acid and / or high temperature and a method of decomposing with an enzyme. A method of hydrolyzing with an acid and / or high temperature is described in JP-A-61-96.
947, JP-A-2-200147 and the like. Spent coffee residue from a commercial coffee multi-stage extraction system can be hydrolyzed by adding an acid catalyst in a reaction vessel, or by treating at a high temperature for a short time without adding an acid catalyst. It can also be obtained by decomposition. It is convenient to use a tubular plug flow reactor, but good results can be obtained using any reactor that is suitable for conducting a reaction at a relatively high temperature for a short time. The reaction time and reaction temperature are adjusted, solubilized and hydrolyzed to decompose the mannan of DP10 to 40 into mannooligosaccharides of DP1 to 10, and then separate from the coffee residue to obtain mannooligosaccharides.
【0025】「マンナン」という用語は、広くd−マン
ノースからなる多糖を意味する。単糖d−マンノースは
アルドヘキソースであり、d−グルコース中のカルボキ
シル基に隣接する炭素に結合している水酸基の立体配置
が逆になっているものである。The term "mannan" refers to a polysaccharide consisting broadly of d-mannose. The monosaccharide d-mannose is an aldohexose, in which the configuration of the hydroxyl group bonded to the carbon adjacent to the carboxyl group in d-glucose is reversed.
【0026】「オリゴ糖」は、単糖の数が比較的少ない
ポリマーを意味する。とくに、本明細書においては、単
糖の数が10以下であるポリマーをさす。マンノース
は、便宜上DP1のオリゴ糖とするが、厳密にいうとオ
リゴ糖は2以上の単糖からなるものをさす。"Oligosaccharide" means a polymer having relatively few monosaccharides. In particular, in the present specification, it refers to a polymer in which the number of monosaccharides is 10 or less. Mannose is a DP1 oligosaccharide for convenience, but strictly speaking, an oligosaccharide refers to one composed of two or more monosaccharides.
【0027】「重合度」または「DP」とは、オリゴ糖
を構成している単糖の数を意味する。従って、たとえば
マンノースが4つの単糖から構成されているマンノオリ
ゴ糖の重合度は4であるのでDP4と記載する。"Degree of polymerization" or "DP" means the number of monosaccharides constituting an oligosaccharide. Therefore, for example, the degree of polymerization of a manno-oligosaccharide in which mannose is composed of four monosaccharides is 4, and is described as DP4.
【0028】「コーヒー残査」とは、たとえば大気条件
中で抽出した後のいわゆるコーヒー抽出粕を意味する。
また、酵素により分解する方法としては、例えばコーヒ
ー抽出残渣を水性媒体に懸濁させ、ここへ例えば市販の
セルラーゼおよびヘミセルラーゼ等を加えて撹拌しなが
ら懸濁させればよい。酵素の量、作用させる温度および
その他の条件としては、通常の酵素反応に用いられる
量、温度、条件であれば特に問題はなく、使用する酵素
の最適作用量、温度、条件およびその他の要因によって
適宜選択すればよい。"Coffee residue" means, for example, so-called coffee extract cake after extraction under atmospheric conditions.
As a method of decomposing with an enzyme, for example, a coffee extraction residue may be suspended in an aqueous medium, and then, for example, a commercially available cellulase, hemicellulase, or the like may be added thereto and suspended with stirring. The amount of the enzyme, the temperature at which it is allowed to act, and other conditions are not particularly limited as long as it is the amount, temperature, and conditions used in a normal enzyme reaction, and may depend on the optimal amount of the enzyme to be used, temperature, conditions, and other factors. What is necessary is just to select suitably.
【0029】上記の方法によって得られたマンノースを
主体とする単糖類が1〜10分子結合したオリゴ糖類を
含有する組成物を含む反応液は、必要に応じて精製を行
う。精製法としては、骨炭、活性炭、炭酸飽充法、吸着
樹脂、マグネシア法等で脱色を行い、イオン交換樹脂、
イオン交換膜、電気透析等で脱塩、脱酸を行う。精製法
の組み合わせおよび精製条件としては、マンノースが1
〜10分子結合したマンノオリゴ糖類を含む反応液中の
色素、塩、および酸等の量およびその他の要因に応じて
適宜選択すればよい。The reaction solution containing a composition containing oligosaccharides having 1 to 10 molecules of monosaccharides mainly composed of mannose obtained by the above method is purified as necessary. As a purification method, decolorization is performed by bone charcoal, activated carbon, carbonation saturation method, adsorption resin, magnesia method, etc.
Desalting and deoxidizing are performed by ion exchange membrane, electrodialysis and the like. The combination of the purification methods and the purification conditions are as follows.
What is necessary is just to select suitably according to the quantity of a pigment | dye, a salt, an acid, etc. in the reaction liquid containing the mannooligosaccharide which couple | bonded 10-10 molecules, and other factors.
【0030】次に、本発明を実施例および試験例により
具体的に説明する。 実施例1 コーヒー抽出残渣を反応器に送りやすくするために、ま
ず粉砕して粒径を約1mmにした。次いで、総固形分濃
度が約14w/w%の水と粉砕物からなるスラリーを調
製し4mの熱栓流反応器内において熱処理した。滞留時
間8分に対応する速度で高圧蒸気とともに栓流反応器に
ポンプ輸送し、6.35mmφオリフィスを用いて約2
10℃に維持した。その後、大気圧下に噴出することに
よって、反応を急止した。できたスラリーを濾過して、
不溶性固形分から可溶性固形分を含む液を分離した。こ
の可溶性固形分含有液を活性炭、吸着樹脂で脱色した
後、イオン交換樹脂で脱塩した。さらに活性炭にて分画
後、濃縮、乾燥してマンノースを主体とする単糖類が1
〜10分子結合したオリゴ糖類を含有する組成物を収率
13%で得た。血清脂質の改善作用の有用性評価に使用
された組成物のDP分布は、DP1;0.6%、DP
2;34.6%、DP3;23.5%、DP4;16.
2%、DP5;12.7%、DP6;8.3%、DP7
以上;4.1%であった。糖鎖中のマンノース残基の含
有量は90%であり、オリゴ糖のDP1としてはマンノ
ース等、DP2としてはマンノビオース等、DP3とし
てはマンノトリオース等、DP4としてはマンノテトラ
オース等、DP5としてはマンノペンタオース等、DP
6としてはマンノヘキサオース等、DP7としてはマン
ノヘプタオース等等で、結合様式はβ−1,4結合であ
る。生後6週齢のSlc:Wistar(SPF)雄性
ラットを使用して、粉末飼料で1週間予備飼育した。1
6時間絶食後にエーテル軽麻酔下で頸静脈より採血を行
い、血清分離後総コレステロールと中性脂肪濃度を自動
分析装置にて測定した。その時の総コレステロール濃度
と体重を基準に連続無作為化法により1群5匹の2群に
分けた上で、試験食(対照群)、本発明に係る組成物を
試験食中に5%となるように添加した試験食(MOS
群)をそれぞれ4週間与えた。試験食の組成を表1に示
した。Next, the present invention will be described specifically with reference to examples and test examples. Example 1 In order to easily send a coffee extraction residue to a reactor, the residue was first ground to a particle size of about 1 mm. Next, a slurry consisting of water and a pulverized product having a total solid content of about 14 w / w% was prepared and heat-treated in a 4 m hot plug flow reactor. Pumped with high pressure steam to the plug flow reactor at a rate corresponding to a residence time of 8 minutes, using a 6.35 mmφ orifice for approximately 2 minutes.
Maintained at 10 ° C. The reaction was then halted by squirting under atmospheric pressure. Filter the resulting slurry,
A liquid containing a soluble solid was separated from an insoluble solid. The solution containing the soluble solid was decolorized with activated carbon and an adsorption resin, and then desalted with an ion exchange resin. After fractionation with activated charcoal, the mixture is concentrated and dried to obtain one monosaccharide mainly composed of mannose.
A composition containing 10 to 10 molecules of linked oligosaccharides was obtained at a yield of 13%. The DP distribution of the composition used to evaluate the usefulness of the serum lipid improving effect was DP1; 0.6%, DP
2; 34.6%, DP3; 23.5%, DP4;
2%, DP5; 12.7%, DP6; 8.3%, DP7
Above: 4.1%. The content of the mannose residue in the sugar chain is 90%, and the oligosaccharide DP1 is mannose or the like, DP2 is mannobiose or the like, DP3 is mannotriose or the like, DP4 is mannotetraose or the like, and DP5 is DP5 or the like. Is mannopentaose, DP
6 is mannohexaose or the like, DP7 is mannoheptaose or the like, and the binding mode is β-1,4 bond. Six-week-old Slc: Wistar (SPF) male rats were pre-fed for 1 week on powdered feed. 1
After fasting for 6 hours, blood was collected from the jugular vein under light anesthesia with ether, and after serum separation, total cholesterol and triglyceride concentration were measured by an automatic analyzer. Based on the total cholesterol concentration and body weight at that time, the rats were divided into two groups of five per group by a continuous randomization method, and the test meal (control group) and the composition according to the present invention were added to the test meal at 5%. Test food (MOS
Group) each for 4 weeks. Table 1 shows the composition of the test meal.
【0031】飼料配合Feed formulation
【表1】 [Table 1]
【0032】飼育は、室温22±3℃、湿度50±20
%、12時間の明暗サイクルの飼育室で行い、飼料及び
飲料水は自由摂取とした。摂取1週と4週に、各群全例
について16時間以上絶食させた状態で、エーテル軽麻
酔下で頸静脈より採血を行い、血清分離後総コレステロ
ールと中性脂肪濃度を自動分析装置にて測定した。結果
を表2に示した。Breeding is performed at room temperature 22 ± 3 ° C. and humidity 50 ± 20.
%, In a breeding room with a 12-hour light-dark cycle, and feed and drinking water were freely available. Blood was collected from the jugular vein under light ether anesthesia in a state in which each group had been fasted for 16 hours or more at 1 week and 4 weeks after ingestion, and after serum separation, total cholesterol and triglyceride concentration were measured with an automatic analyzer It was measured. The results are shown in Table 2.
【0033】血清脂質の変化Changes in serum lipids
【表2】 摂取1週目から効果が現われ、4週後において、MOS
群は対照群と比べて総コレステロール及び中性脂肪とも
有意に上昇が抑制されていることが明らかとなった。[Table 2] The effect appears from the first week of ingestion, and after 4 weeks, MOS
It became clear that the increase in both total cholesterol and neutral fat was significantly suppressed in the group as compared with the control group.
【0034】実施例2 高脂血症の被験者1名(46歳、男性)を対象として本
発明に係る組成物の効果を検証した。被験者は本試験開
始3週間前から試験期間中を通じて、薬物投与や生菌剤
(乳酸菌製品)を摂取していないが、その他の食事制限
は行わなかった。代表例の組成を持つマンノオリゴ糖の
乾燥粉末3gを1日1回飲料に溶かして連続2週間摂取
させた。摂取前と摂取期間の終わりに採血し総コレステ
ロールと中性脂肪を測定した。その結果を表3に示し
た。Example 2 The effect of the composition according to the present invention was verified on one subject (46 years old, male) with hyperlipidemia. The subjects did not administer any drugs or took any probiotic agents (lactic acid bacteria products) from 3 weeks before the start of the test to throughout the test period, but did not perform any other dietary restrictions. 3 g of a dry powder of mannooligosaccharide having the composition of the representative example was dissolved in a beverage once a day and ingested for two consecutive weeks. Blood was collected before and at the end of the intake period to measure total cholesterol and triglycerides. Table 3 shows the results.
【0035】血清脂質の変化Changes in serum lipids
【表3】 [Table 3]
【0036】実施例3 コーヒーミックスの製造法 インスタントコーヒー2.0gとマンノオリゴ糖粉末
0.5gとクリーミングパウダー3.0gとを混合しコ
ーヒーミックスを調製した。このミックスをお湯140
mlで溶かし、官能評価した結果、従来のミルクコーヒ
ーの味を充分維持し、しかも、より濃厚で味わい深いコ
ーヒー飲料となった。この飲料を飲用し続ければ血液中
の脂質の上昇抑制効果が期待できる。Example 3 Method for Producing a Coffee Mix A coffee mix was prepared by mixing 2.0 g of instant coffee, 0.5 g of manno-oligosaccharide powder and 3.0 g of creaming powder. Add this mix to hot water 140
As a result of dissolving the mixture in ml and performing a sensory evaluation, the taste of the conventional milk coffee was sufficiently maintained, and a thicker and more flavored coffee beverage was obtained. If this drink is continued to be taken, an effect of suppressing an increase in blood lipid can be expected.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 FI テーマコート゛(参考) A61K 31/715 A61K 31/715 A61P 3/04 A61P 3/04 3/06 3/06 Fターム(参考) 2B150 AB20 DC13 DC15 4B018 LB08 LE03 MD27 MD28 MD29 MD48 ME04 4B027 FB24 FB28 FC06 FE02 FK04 4B041 LC10 LD10 LE01 LH01 LH07 LK10 LK11 LP05 LP25 4C086 AA01 AA02 EA01 EA20 MA01 MA04 NA14 ZC33 ──────────────────────────────────────────────────の Continued on the front page (51) Int.Cl. 7 Identification symbol FI Theme coat ゛ (Reference) A61K 31/715 A61K 31/715 A61P 3/04 A61P 3/04 3/06 3/06 F-term (reference) 2B150 AB20 DC13 DC15 4B018 LB08 LE03 MD27 MD28 MD29 MD48 ME04 4B027 FB24 FB28 FC06 FE02 FK04 4B041 LC10 LD10 LE01 LH01 LH07 LK10 LK11 LP05 LP25 4C086 AA01 AA02 EA01 EA20 MA01 MA04 NA14 ZC33
Claims (7)
分子結合したオリゴ糖類又はマンノースとグルコースお
よびガラクトースのような単糖類の少なくとも1種とが
1〜10分子結合したマンノースを主体としたオリゴ糖
類を主成分とすることを特徴とする血清脂質の改善作用
を有する組成物。(1) a monosaccharide mainly containing mannose is 1 to 10:
Serum lipid improving activity characterized in that the main component is a mannose-based oligosaccharide in which 1 to 10 molecule-bound oligosaccharides or mannose and at least one monosaccharide such as glucose and galactose are bound. A composition comprising:
単糖類が1〜10分子結合したオリゴ糖類又はマンノー
スとグルコースおよびガラクトースのような単糖類の少
なくとも1種とが1〜10分子結合したマンノースを主
体としたオリゴ糖類の合計含有割合が60w/w%以上
である請求項1に記載の組成物。2. An oligosaccharide in which 1 to 10 molecules of a monosaccharide mainly composed of mannose are bonded to the total solid content, or 1 to 10 molecules of a mannose and at least one type of monosaccharide such as glucose and galactose are bonded. The composition according to claim 1, wherein the total content of oligosaccharides mainly composed of mannose is 60 w / w% or more.
70w/w%以上である請求項1乃至2のいずれかに記
載の組成物。3. The composition according to claim 1, wherein the ratio of mannose residues is at least 70 w / w% in the saccharide composition.
ンノースが2〜6分子結合したオリゴ糖類の中から選ば
れた1種以上であることを特徴とする請求項1乃至2の
いずれかに記載の組成物。4. The method according to claim 1, wherein the oligosaccharide mainly composed of mannose is at least one selected from oligosaccharides having 2 to 6 molecules of mannose bonded thereto. Composition.
がマンナンを加水分解処理することによって得られる組
成物。5. A composition obtained by subjecting the composition according to claim 1 to hydrolysis treatment of mannan.
はコーヒー抽出残渣から得られるものである請求項1乃
至5のいずれかに記載の組成物。6. The composition according to claim 1, wherein said mannan is obtained from coffee bean and / or coffee extract residue.
を含有する飲食物または飼料。7. A food, drink or feed containing the composition according to any one of claims 1 to 6.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001070385A JP2002262827A (en) | 2001-03-13 | 2001-03-13 | Serum lipid improving composition containing mannooligosaccharide |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001070385A JP2002262827A (en) | 2001-03-13 | 2001-03-13 | Serum lipid improving composition containing mannooligosaccharide |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006007023A Division JP4673753B2 (en) | 2006-01-16 | 2006-01-16 | Serum lipid improving agent containing mannooligosaccharide |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2002262827A true JP2002262827A (en) | 2002-09-17 |
Family
ID=18928267
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2001070385A Pending JP2002262827A (en) | 2001-03-13 | 2001-03-13 | Serum lipid improving composition containing mannooligosaccharide |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2002262827A (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002262828A (en) * | 2001-03-13 | 2002-09-17 | Ajinomoto General Foods Inc | Composition for suppressing increase of lipid peroxide level containing mannooligosaccharide |
JP2006083127A (en) * | 2004-09-17 | 2006-03-30 | Ajinomoto General Foods Inc | Composition having body fat reducing action and food and drink containing the same |
JP2006169135A (en) * | 2004-12-14 | 2006-06-29 | Ajinomoto General Foods Inc | Anti-allergen composition containing mannooligosaccharides |
WO2007086100A1 (en) * | 2006-01-24 | 2007-08-02 | Ajinomoto General Foods, Inc. | Composition having effect of lowering blood pressure and/or inhibiting increase in blood pressure and food and drink containing the same |
JP2009275047A (en) * | 2009-06-30 | 2009-11-26 | Ajinomoto General Foods Inc | Composition having body fat reducing action and food and drink containing the same |
JP2011132187A (en) * | 2009-12-25 | 2011-07-07 | Suntory Holdings Ltd | Method for producing mannooligosaccharide |
KR20120008036A (en) * | 2009-03-26 | 2012-01-25 | 아지노모또 제네럴 푸즈, 인크. | Pharmaceutical composition for preventing or treating lifestyle diseases and foods that help |
JP2014128197A (en) * | 2012-12-27 | 2014-07-10 | Kao Corp | Acidic beverage |
JP2014128198A (en) * | 2012-12-27 | 2014-07-10 | Kao Corp | Packed beverage |
AU2012201716B2 (en) * | 2004-09-17 | 2014-11-13 | Ajinomoto General Foods, Inc. | Compositions having body fat reducing function and food and drink containing the same |
JP5702713B2 (en) * | 2009-03-26 | 2015-04-15 | 味の素ゼネラルフーヅ株式会社 | Pharmaceutical composition for promoting adiponectin production and food useful therefor |
JP5738180B2 (en) * | 2009-03-26 | 2015-06-17 | 味の素ゼネラルフーヅ株式会社 | Pharmaceutical composition and food useful for preventing or treating lifestyle-related diseases |
JP2015129126A (en) * | 2015-01-06 | 2015-07-16 | サントリーホールディングス株式会社 | Manno-oligosaccharide production method |
JP2016179988A (en) * | 2016-04-28 | 2016-10-13 | サントリーホールディングス株式会社 | Method for producing mannooligosaccharide |
AU2018284983B2 (en) * | 2017-06-14 | 2024-07-25 | Cargill, Incorporated | Composition comprising mannose oligosaccharide and process for making same and use thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6196947A (en) * | 1984-10-19 | 1986-05-15 | ゼネラル・フ−ヅ・コ−ポレ−シヨン | Production of mannan oligomer hydrolysate |
JPH05246860A (en) * | 1992-02-20 | 1993-09-24 | Morinaga Milk Ind Co Ltd | Colorectal cancer preventive agent |
JP2000217546A (en) * | 1999-01-29 | 2000-08-08 | Showa Sangyo Co Ltd | A sweetener comprising a mannose-containing hetero-oligosaccharide, an agent for suppressing pathogen infection, an intestinal suppressant or an agent for suppressing aging of starch, and a food, beverage, medicine or feed comprising the agent. |
JP2000297040A (en) * | 1999-04-14 | 2000-10-24 | Unitika Ltd | Anticariogenic composition and food and beverage |
-
2001
- 2001-03-13 JP JP2001070385A patent/JP2002262827A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6196947A (en) * | 1984-10-19 | 1986-05-15 | ゼネラル・フ−ヅ・コ−ポレ−シヨン | Production of mannan oligomer hydrolysate |
JPH05246860A (en) * | 1992-02-20 | 1993-09-24 | Morinaga Milk Ind Co Ltd | Colorectal cancer preventive agent |
JP2000217546A (en) * | 1999-01-29 | 2000-08-08 | Showa Sangyo Co Ltd | A sweetener comprising a mannose-containing hetero-oligosaccharide, an agent for suppressing pathogen infection, an intestinal suppressant or an agent for suppressing aging of starch, and a food, beverage, medicine or feed comprising the agent. |
JP2000297040A (en) * | 1999-04-14 | 2000-10-24 | Unitika Ltd | Anticariogenic composition and food and beverage |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002262828A (en) * | 2001-03-13 | 2002-09-17 | Ajinomoto General Foods Inc | Composition for suppressing increase of lipid peroxide level containing mannooligosaccharide |
KR101203778B1 (en) | 2004-09-17 | 2012-11-21 | 크래프트 푸드 글로벌 브랜드 엘엘씨 | Compositions having body fat reducing function and food and drink containing the same |
JP2006083127A (en) * | 2004-09-17 | 2006-03-30 | Ajinomoto General Foods Inc | Composition having body fat reducing action and food and drink containing the same |
EP1809328A4 (en) * | 2004-09-17 | 2007-11-14 | Ajinomoto General Foods Inc | Compositions having body fat reducing function and food and drink containing the same |
AU2012201716B2 (en) * | 2004-09-17 | 2014-11-13 | Ajinomoto General Foods, Inc. | Compositions having body fat reducing function and food and drink containing the same |
AU2005290262B2 (en) * | 2004-09-17 | 2012-01-12 | Ajinomoto General Foods, Inc. | Compositions having body fat reducing function and food and drink containing the same |
JP2006169135A (en) * | 2004-12-14 | 2006-06-29 | Ajinomoto General Foods Inc | Anti-allergen composition containing mannooligosaccharides |
WO2007086100A1 (en) * | 2006-01-24 | 2007-08-02 | Ajinomoto General Foods, Inc. | Composition having effect of lowering blood pressure and/or inhibiting increase in blood pressure and food and drink containing the same |
KR101300336B1 (en) * | 2006-01-24 | 2013-08-28 | 아지노모또 제네럴 푸즈, 인크. | Composition having effect of lowering blood pressure and/or inhibiting increase in blood pressure and food and drink containing the same |
JP5702713B2 (en) * | 2009-03-26 | 2015-04-15 | 味の素ゼネラルフーヅ株式会社 | Pharmaceutical composition for promoting adiponectin production and food useful therefor |
US9101648B2 (en) | 2009-03-26 | 2015-08-11 | Intercontinental Great Brands Llc | Pharmaceutical composition comprising mannooligosaccharides derived from coffee for treatment of lifestyle-related disease, and food useful for treatment of lifestyle-related disease |
KR20120008036A (en) * | 2009-03-26 | 2012-01-25 | 아지노모또 제네럴 푸즈, 인크. | Pharmaceutical composition for preventing or treating lifestyle diseases and foods that help |
KR101723529B1 (en) * | 2009-03-26 | 2017-04-05 | 아지노모또 제네럴 푸즈, 인크. | Pharmaceutical composition for prevention or treatment of lifestyle-related disease, and food useful for prevention or treatment of lifestyle-related disease |
EP2412375A4 (en) * | 2009-03-26 | 2012-09-26 | Ajinomoto General Foods Inc | PHARMACEUTICAL COMPOSITION FOR PREVENTION BZW. TREATMENT OF DISEASES RELATED TO LIFESTYLE AND FOOD FOR PREVENTION TREATMENT OF DISEASES IN CONNECTION WITH LIFESTYLE |
JP5738180B2 (en) * | 2009-03-26 | 2015-06-17 | 味の素ゼネラルフーヅ株式会社 | Pharmaceutical composition and food useful for preventing or treating lifestyle-related diseases |
JP2009275047A (en) * | 2009-06-30 | 2009-11-26 | Ajinomoto General Foods Inc | Composition having body fat reducing action and food and drink containing the same |
JP2011132187A (en) * | 2009-12-25 | 2011-07-07 | Suntory Holdings Ltd | Method for producing mannooligosaccharide |
JP2014128198A (en) * | 2012-12-27 | 2014-07-10 | Kao Corp | Packed beverage |
JP2014128197A (en) * | 2012-12-27 | 2014-07-10 | Kao Corp | Acidic beverage |
JP2015129126A (en) * | 2015-01-06 | 2015-07-16 | サントリーホールディングス株式会社 | Manno-oligosaccharide production method |
JP2016179988A (en) * | 2016-04-28 | 2016-10-13 | サントリーホールディングス株式会社 | Method for producing mannooligosaccharide |
AU2018284983B2 (en) * | 2017-06-14 | 2024-07-25 | Cargill, Incorporated | Composition comprising mannose oligosaccharide and process for making same and use thereof |
JP7607063B2 (en) | 2017-06-14 | 2024-12-26 | カーギル インコーポレイテッド | Compositions containing mannose oligosaccharides, methods for producing same and uses of same |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4771882B2 (en) | Composition having action of treating, preventing or ameliorating diabetes or diabetic complication and beverage containing the same | |
JPH0678367B2 (en) | Dietary fiber, method for producing the same, and bioactive agent containing the dietary fiber | |
JPH0728694B2 (en) | Food composition having intestinal regulating action | |
JP5214978B2 (en) | Composition having blood pressure lowering action and / or elevation suppressing action and food and drink containing the same | |
JP2002262827A (en) | Serum lipid improving composition containing mannooligosaccharide | |
JP3553866B2 (en) | Composition based on mannooligosaccharides | |
JP2006083127A (en) | Composition having body fat reducing action and food and drink containing the same | |
JP2004159659A (en) | Composition mainly composed of mannooligosaccharide | |
JP4684440B2 (en) | Lipid peroxide elevation-suppressing composition containing mannooligosaccharide | |
JP4307800B2 (en) | Immunostimulating composition containing mannooligosaccharide | |
JP4673753B2 (en) | Serum lipid improving agent containing mannooligosaccharide | |
JP3515078B2 (en) | Taste improvement of food and drink by coffee oligosaccharide | |
JP4851215B2 (en) | Mineral absorption promoting composition containing mannooligosaccharide | |
JP5702713B2 (en) | Pharmaceutical composition for promoting adiponectin production and food useful therefor | |
JP6287479B2 (en) | Anticancer drug | |
JP2002306093A (en) | Promoting composition including mannooligosaccharide for mineral absorption | |
JP4960591B2 (en) | Anti-allergen composition containing mannooligosaccharides | |
JP6269251B2 (en) | Skin quality improver | |
JP2009275047A (en) | Composition having body fat reducing action and food and drink containing the same | |
JP6303714B2 (en) | DNA damage inhibitor and method for producing the same | |
JP6418310B2 (en) | Mannopolyosyl fructose production method, oligosaccharide composition, and microorganism culture medium | |
JP2024160499A (en) | Oligosaccharide composition and mannooligosaccharide-containing water | |
JP2025076880A (en) | Anti-fatigue drugs for cancer-related fatigue | |
JP2011140516A (en) | Composition having function of treating, preventing or ameliorating diabetes or diabetic complication, and drink containing the same | |
CN1772039A (en) | Product of coromandel and method for its use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040621 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20050920 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050930 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051124 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20051215 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060116 |
|
A911 | Transfer of reconsideration by examiner before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20060228 |
|
A912 | Removal of reconsideration by examiner before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20060324 |